Clinical Trials

30 enrolled

Phase 3 Active not recruiting

Mycosis Fungoides

NCT03907488 2025-12-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts

Phase 3 Enrolling by invitation

Hodgkin Disease

NCT07258680 2025-12-02

BrEto-TCL

114 enrolled

Lymphoma, T-Cell, Peripheral

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

23 enrolled 15 charts

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02227199 2025-11-18

BV-ICE

Phase 1/2 Completed

45 enrolled 14 charts

Hodgkin Disease

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

48 enrolled 8 charts

Phase 1/2 Active not recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

59 enrolled 63 charts

Hodgkin Disease

NCT03587844 2025-11-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

58 enrolled

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT07002216 2025-11-03

BrECADD

48 enrolled

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

66 enrolled 14 charts

Hodgkin Disease

NCT07013565 2025-10-21

ACCELERATE

20 enrolled

Lymphoma, Large-Cell, Anaplastic

NCT05922904 2025-10-10

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

25 enrolled

Hodgkin Disease

NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4 Completed

50 enrolled 22 charts

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT05442554 2025-09-18

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 4 Completed

10 enrolled 25 charts

Phase 3 Not yet recruiting

Lymphoma, T-Cell

NCT07178457 2025-09-17

BeCALM

84 enrolled

Lymphoma, T-Cell, Cutaneous

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT02734771 2025-08-12

BV mini CHP

24 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

40 enrolled

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT05414500 2025-08-08

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

10 enrolled

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

71 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

26 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

52 enrolled

Phase NA Active not recruiting

Lymphoma

NCT01868451 2025-07-09

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

118 enrolled

Hodgkin Disease

NCT01703949 2025-06-11

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

28 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03057795 2025-05-07

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

62 enrolled 8 charts

Hodgkin Disease

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

23 enrolled

Lymphoma, Follicular

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Hodgkin Disease

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

16 enrolled

Lymphoma, T-Cell, Cutaneous

NCT03187210 2025-03-30

BAL

Phase 1/2 Suspended

20 enrolled

Lymphoma

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

32 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Hodgkin Disease, Recurrence

NCT03264131 2025-02-10

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

16 enrolled 8 charts